Peringatan Keamanan

Adverse effects include diarrhea, nausea, stomach upset, vomiting, headache, dizziness, rash, bone marrow depression.

Loracarbef

DB00447

small molecule approved investigational withdrawn

Deskripsi

Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

Struktur Molekul 2D

Berat 349.769
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1 hour. In subjects with moderate impairment of renal function the plasma half-life was prolonged to approximately 5.6 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Well absorbed with approximately 90% absorbed from the gastrointestinal tract after oral ingestion.

Metabolisme

There is no evidence of metabolism in humans.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take on an empty stomach. Food decreases absorption.

Interaksi Obat

796 Data
Probenecid The serum concentration of Loracarbef can be increased when it is combined with Probenecid.
Foscarnet The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Loracarbef.
Tenofovir disoproxil Loracarbef may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Loracarbef may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Loracarbef may increase the nephrotoxic activities of Tenofovir.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Loracarbef.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Loracarbef.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Loracarbef.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Loracarbef.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Loracarbef.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Loracarbef.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Loracarbef.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Loracarbef.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Loracarbef.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Loracarbef.
Cefalotin The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefalotin.
Nabumetone The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Nabumetone.
Ketorolac The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Ketorolac.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Tenoxicam.
Celecoxib The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Celecoxib.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefotaxime.
Tolmetin The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Tolmetin.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Rofecoxib.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Fenoprofen.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Valdecoxib.
Diclofenac The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Diclofenac.
Sulindac The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Sulindac.
Bacitracin The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Bacitracin.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Amphotericin B.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cephaloglycin.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Adefovir dipivoxil.
Pentamidine The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Pentamidine.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Mefenamic acid.
Naproxen The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Naproxen.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Sulfasalazine.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Phenylbutazone.
Meloxicam The risk or severity of methemoglobinemia can be increased when Loracarbef is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Carprofen.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Tacrolimus.
Etacrynic acid The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Etacrynic acid.
Ceforanide The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Ceforanide.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Salicylic acid.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Acetylsalicylic acid.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Hydrochlorothiazide.
Balsalazide The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Balsalazide.
Cefditoren The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefditoren.
Atazanavir The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Atazanavir.
Colistimethate The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Colistimethate.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefuroxime.
Cefapirin The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefapirin.
Cefprozil The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefprozil.
Olsalazine The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Olsalazine.
Lumiracoxib The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Lumiracoxib.
Cefamandole The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefamandole.
Cefazolin The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefazolin.
Cefonicid The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefonicid.
Cefoperazone The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefoperazone.
Cefoxitin The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefoxitin.
Ceftizoxime The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Ceftizoxime.
Magnesium salicylate The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Magnesium salicylate.
Salsalate The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Salsalate.
Choline magnesium trisalicylate The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Choline magnesium trisalicylate.
Cefepime The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefepime.
Cefacetrile The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefacetrile.
Cefpodoxime The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefpodoxime.
Antrafenine The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Antrafenine.
Aminophenazone The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Aminophenazone.
Antipyrine The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Antipyrine.
Tiaprofenic acid The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Tiaprofenic acid.
Lopinavir The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Lopinavir.
Etoricoxib The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Etoricoxib.
Hydrolyzed Cephalothin The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Hydrolyzed Cephalothin.
Cephalothin Group The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cephalothin Group.
Oxyphenbutazone The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Oxyphenbutazone.
Latamoxef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Latamoxef.
Nimesulide The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Nimesulide.
Benoxaprofen The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Benoxaprofen.
Metamizole The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Metamizole.
Zomepirac The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Zomepirac.
Ceftobiprole The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Ceftobiprole.
Cimicoxib The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cimicoxib.
Ceftaroline fosamil The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Ceftaroline fosamil.
Lornoxicam The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Lornoxicam.
Zaltoprofen The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Zaltoprofen.
Azapropazone The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Azapropazone.
Parecoxib The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Parecoxib.
Salicylamide The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Salicylamide.
Kebuzone The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Kebuzone.
Isoxicam The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Isoxicam.
Indoprofen The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Indoprofen.
Ibuproxam The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Ibuproxam.
Floctafenine The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Floctafenine.
Fenbufen The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Fenbufen.
Etofenamate The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Etofenamate.
Epirizole The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Epirizole.
Cefaloridine The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefaloridine.
Cefminox The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefminox.
Dexibuprofen The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Dexibuprofen.
Droxicam The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Droxicam.

Target Protein

Penicillin-binding protein 3 pbp3
Penicillin-binding protein 1A pbpA

Referensi & Sumber

Synthesis reference: William C. Henning, Theodore R. Stout, "Process for preparing loracarbef monohydrate." U.S. Patent US5580977, issued May, 1990.
Artikel (PubMed)
  • PMID: 8155686
    Dantzig AH, Duckworth DC, Tabas LB: Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells. Biochim Biophys Acta. 1994 Apr 20;1191(1):7-13.
  • PMID: 7686466
    Brogden RN, McTavish D: Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993 May;45(5):716-36.
  • PMID: 8453172
    Force RW, Nahata MC: Loracarbef: a new orally administered carbacephem antibiotic. Ann Pharmacother. 1993 Mar;27(3):321-9.
  • PMID: 1621741
    Copper RD: The carbacephems: a new beta-lactam antibiotic class. Am J Med. 1992 Jun 22;92(6A):2S-6S.

Contoh Produk & Brand

Produk: 5 • International brands: 2
Produk
  • Lorabid
    Capsule • 200 mg/1 • Oral • US • Approved
  • Lorabid
    Capsule • 400 mg/1 • Oral • US • Approved
  • Lorabid
    Suspension • 100 mg/5mL • Oral • US • Approved
  • Lorabid
    Suspension • 200 mg/5mL • Oral • US • Approved
  • Lorabid
    Capsule • 200 mg/1 • Oral • US • Approved
International Brands
  • Lorafem — Pierre Fabre
  • Lorbef — Lilly

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul